PURE Bioscience (OTCMKTS:PURE) Releases Earnings Results

PURE Bioscience (OTCMKTS:PURE) posted its quarterly earnings data on Monday. The company reported ($0.01) EPS for the quarter, Zacks reports.

PURE Bioscience Stock Up 25.1 %

Shares of PURE stock traded up $0.01 on Monday, reaching $0.07. The stock had a trading volume of 1,477 shares, compared to its average volume of 58,446. The firm’s 50-day moving average is $0.07 and its two-hundred day moving average is $0.08. The firm has a market capitalization of $7.70 million, a price-to-earnings ratio of -1.72 and a beta of 0.35. PURE Bioscience has a 12 month low of $0.05 and a 12 month high of $0.16.

PURE Bioscience Company Profile

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.